A simple, rapid and stability-indicating chiral HPLC (CHR-HPLC) method was designed for the enantiomeric separation of lenalidomide (LDM) in the presence of its degradation products. LDM was exposed to different accelerated stress factors. The degradation products were well resolved from the pure drug enantiomers. Separation of the LDM enantiomers was achieved on a LUX 5U cellulose-2 chiral column (250 × 4.6 mm i.d.) with a mobile phase consisting of methanol : glacial acetic acid : triethyl amine (100 : 0.01 : 0.01, v/v/v) at a flow rate of 1.2 mL/min. The detection wavelength was 220 nm, and ornidazole was the internal standard. The chiral method was validated in terms of its specificity, linearity, range, precision and accuracy as well as solution stability, robustness, limit of detection and limit of quantification. The calibration curve was linear for concentrations ranging from 2 to 1,000 ng/mL (r = 0.9999) for both LDM enantiomers. The proposed method, which met International Conference on Harmonization/Food and Drug Administration regulatory requirements, was utilized successfully for the determination of LDM in bulk and in capsules with acceptable accuracy and precision; the label demand percentages were 100.09 ± 0.80 and 99.97 ± 0.93 for the S-(−) and R-(+)-LDM enantiomers, respectively. Based on these results, this method should have great value when applied to quality control and stability studies of LDM.
Introduction
Lenalidomide (LDM, Figure 1 ) is a novel oral immune modulatory drug with antiangiogenic and antineoplastic effects (1) . It is structurally related to thalidomide, but exhibits an improved toxicity profile and more potent immunomodulatory activity (2) . LDM is used in the treatment of hematological malignancies, particularly multiple myeloma and a myelodysplastic syndrome subset (3) (4) (5) (6) . LDM has shown promise in Phase II studies for chronic lymphocytic leukemia, non-Hodgkin's lymphoma, amyloidosis and myelofibrosis with myeloid metaplasia (7) (8) (9) (10) . The strong evidence-based clinical success of LDM has led to its recent approval by the US Food and Drug Administration (US-FDA) under the trade name Revlimid ® by Celgene Corporation (New Jersey, USA) (11).
Ahuja and Alsante (12, 13) indicated that the quality of pharmaceutical products, in terms of stability and purity of the active substance and/or finished product, is vital for the effective and safe delivery of its therapeutic values to patients because the presence of impurities and/or potential degradation products may change the chemical, pharmacological and/or toxicological properties of the active drug entity. Environmental conditions including humidity, temperature and light are crucial for pharmaceuticals. Normally, these factors vary depending on the manufacturing, transportation, storage and distribution of the finished product. For these reasons, it is essential that we identify and understand the effects of potential degradation products, possible degradation pathways for the drug, the compatibility of the drug with the excipients in the finished product and the long-term effects of environmental factors on the active drug and its finished products. Stability test results are important for developing the optimal manufacturing process, selecting the proper packaging, storage conditions and product shelf life, and determining the expiration date (14, 15) . Furthermore, climates vary widely worldwide, such that the quality of pharmaceutical LDM is greatly influenced by changes in environmental factors. In addition, LDM capsules are imported from many countries, resulting in significant concerns regarding its quality after exposure to transportation, storage and other conditions. Therefore, quality control for LDM-containing capsules in the countries in which they are produced is a critical concern. Despite an extensive literature survey, no reports regarding stabilityindicating assays for LDM enantiomers have been found. Therefore, a stability-indicating method for determining LDM in its bulk form and in pharmaceutical capsules is particularly essential, as such methods are an important part of any analytical method validation and International Conference on Harmonization (ICH) guidance for the pharmaceutical industry (15) .
Like stability-indicating studies, enantioseparation greatly influences the pharmacological and toxicological properties of chiral drugs. Thus, the separation of enantiomers has become very important in analytical chemistry, particularly in quantifying drugs with regard to their pharmaceutical dosage and forms and/or their use in biological fields of study. This is because some stereoisomers of racemic drugs have significantly different pharmacokinetics and different pharmacological or toxicological effects (16) .
LDM can exist as optically active S-(−) and R-(+) forms and is produced as a racemic mixture with an optical rotation of zero. The S and R enantiomers of LDM are stable to racemization when stored at −70°C in buffered (acidic or neutral pH) plasma. The enantiomers undergo significant nonenzymatic racemization in plasma at 37°C at neutral or alkaline pH (17) .
An extensive literature survey revealed few reports concerning LDM analysis. Sastry et al. (18) reported two spectrophotometric methods for the quantitation of LDM in its pharmaceutical formulations, but these methods did not measure stability. A reversed-phase liquid chromatographic method with UV detection was developed for determination of LDM in the presence of process-related impurities in capsules (19) . Reddy et al. (20) developed an HPLC method for determination of LDM and its related substances. Darwish et al. (21) developed a fluorimetric derivatization method for determination of LDM in its bulk form and in capsules. None of these reported methods for chiral determination of LDM in the presence of its degradation products were capable of measuring stability. For these reasons, the present study was geared toward the development and validation of a stability-indicating HPLC method for the determination of LDM enantiomers in bulk form and in pharmaceutical formulations (capsules).
Experimental

Instrumentation and chromatographic conditions
The LC system employed in the present study was manufactured by WA-TERS (Milford, MA, USA). The instrument was equipped with a Waters 2489 dual-wavelength ultraviolet-visible detector, a Waters 1525 Binary LC pump and a Waters 2707 autosampler. The data handling system included a Dell personal computer and Empower 2 software. Ultrapure water (18 MΩ/cm) was obtained from a Milli-Q Plus purification system (Millipore Waters, Milford, MA, USA). Detection was obtained at 220 nm. Separation employed a LUX 5U Cellulose-2 chiral column (250 × 4.6 mm i.d.). The mobile phase consisted of methanol : glacial acetic acid (HAc) : triethylamine (TEA) (100 : 0.01 : 0.01, v/v/v), delivered at a flow rate of 1.2 mL/min. The mobile phase was filtered using a 0.22-µm nylon filter and sonicated for 15 min. Analyses were performed at ambient temperature. The injection volume was 50 µL. 
Materials and reagents
Preparation of standard solutions and construction of calibration graphs
The standard solution of LDM (1 mg/mL) was prepared in methanol. This stock solution was further diluted with methanol to obtain a working solution of 5 µg/mL. Aliquots of the working solution were transferred to 10-mL volumetric flasks, and l mL of the IS working solution (5 µg/mL) was added to each flask. Subsequently, methanol was added to yield final LDM concentrations of 2, 5, 25, 50, 100, 500 and 1,000 ng/mL. Samples at each concentration were injected in triplicate. The ratio of the peak area of each LDM enantiomer to that of the IS was plotted as a function of the corresponding standard LDM concentration to construct a calibration curve, which was used to derive the corresponding regression equation.
Preparation of Revlimid ® capsule solutions
The contents of 10 capsules, labeled as containing 5 mg of LDM per capsule, were emptied and weighed. Five-milligram samples of accurately weighed LDM were transferred to 10-mL volumetric flasks containing 5 mL methanol. The solutions were stirred and sonicated for 20 min, after which methanol was added to the desired volume. The resulting solutions were well mixed and centrifuged at 3,000 r.p.m. for 10 min. The solutions were then diluted to obtain working capsule solutions of a concentration of 5 µg/mL. Accurate 1-mL volumes of these solutions were transferred to 10-mL volumetric flasks; then, 1 mL of the IS working solution was added. Then methanol was added to each flask until the desired volume was obtained. This LDM solution (500 ng/mL) was analyzed using the proposed CHR-HPLC method.
Forced degradation studies
In accordance with ICH regulatory guidance for stress testing (15) , forced degradation studies of solid-and solution-state LDM in bulk form and in capsules were performed. Each solution used in the forced degradation studies was prepared by dissolving LDM in a small volume of methanol and diluting with hydrogen peroxide, aqueous 0.5 N hydrochloric acid or aqueous 0.5 N sodium hydroxide to achieve a concentration of 500 ng/mL. Subsequent photodegradation studies were performed in methanol. The solutions were exposed to sunlight during the day for 10 days. The resulting solutions were analyzed every day. Control samples, which were protected from light using aluminum foil, were concurrently placed in daylight.
For thermal stress studies, samples of drug substances were placed in a controlled-temperature oven at 60 ± 2°C for 10 days, and the resulting solutions were analyzed every day.
Results
Method development
During the last few years, polar organic mobile phases have been used successfully with polysaccharide columns (22) . Compared with the normal-phase mode, the organic mode improved solubility, increased resolution and decreased analysis time. However, very few reports have indicated when using a polar organic mode is feasible and whether acid/base additives are required for suitable chromatography to be obtained (22) . The present study employed easily prepared mobile phases composed of methanol with small amounts of HAc and TEA. On the LUX 5U cellulose-2-chiral column, baseline separation of LDM was achieved using a polar organic mobile phase consisting of methanol : glacial HAc : TEA (100 : 0.01 : 0.01, v/v/v); a representative chromatogram is given in Figure 2 . Adding small amounts of TEA and HAc to the mobile phase prevented peak tailing and enhanced chromatographic efficiency and peak symmetry and resolution between the LDM enantiomers. The system suitability parameters, including retention time (t r ), separation factor (α), retention factor (k) and resolution, are shown in Table I .
Method validation
Specificity
The intact LDM drug was completely resolved from its degradation products without interference, indicating that the proposed method exhibits suitable specificity. In addition, the proposed method exhibits high selectivity; the excipients commonly coformulated with LDM (e.g., lactose anhydrous, magnesium stearate, microcrystalline cellulose, starch and croscarmellose sodium) did not interfere with determination of the LDM enantiomers. 
Forced degradation studies
The results obtained from the stress tests have been summarized in Table II . LDM was found to be stable under UV irradiation and exposure to dry heat, as no significant degradation products were detected in subsequent chromatograms, which were identical to the chromatogram of the nonstressed LDM sample (Figure 3b and e) . In addition, the recovery values of the intact LDM enantiomers in these stressed samples were 100.0, 100.0 and 99.97%, and 100.64% in the case of UV irradiation and exposure to dry heat (Table II) . Minor degradation was detected in the case of acid hydrolysis (Figure 3c ), while significant degradation was observed in the case of alkali hydrolysis. In the cases of both acid and alkali hydrolysis, the proposed CHR-HPLC method was capable of completely separating the degradation products from the intact LDM enantiomers. Moreover, no observed degradation was observed upon oxidation by H 2 O 2 . These results confirmed the selectivity and stability-indicating properties of the proposed method. The chromatographic profiles for the degradation studies are shown in Figure 3 .
Linearity, limits of detection and limits of quantitation As seen in Table III , calibration curves were linear in the range of 2-1,000 ng/mL for each enantiomer, and excellent correlation coefficients (r = 0.9999) were obtained for both enantiomers. The regression equations were as follows: y = -0.0061 + 0.0071x and y= −0.001 + 0.0069x for the S-LND and R-LND enantiomers, respectively. The limits of detection (LOD) and quantitation (LOQ) were determined to be 1 and 2 ng/mL for the S-(−)-LND and R-(+)-LND enantiomers when signal-to-noise ratios of 3 and 10 were used as criteria for the LOD and LOQ, respectively. The standard LDM (500 ng/mL), which was not subjected to stress conditions. (b-f) Samples that were subjected to dry heat, acid hydrolysis, alkaline hydrolysis, UV irradiation and oxidative degradation, respectively.
Accuracy and precision
The accuracies obtained (reported as % errors) are excellent for both S-(−) and R-(+)-LDM enantiomers, as the errors did not exceed 2.20% (Table IV) . Intra-and interday precision [reported as the relative standard deviation (%RSD)] studies were performed at three different concentration levels (25, 100 and 500 ng/mL) for each LDM enantiomer (n = 3). The results obtained indicate high degrees of repeatability and reproducibility for the proposed method, as the RSD did not exceed 1.21% (Table IV) .
Sample solution stability
The stability of each stock solution was determined by analyzing each enantiomeric solution after 1 month of storage, and the results were compared with those of freshly prepared standard solutions. Significant changes were observed in the responses of the stored solutions relative to freshly prepared standards. The S-(−) and R-(+) enantiomers of LDM undergo significant racemization from R-(+) to S-(−), and the ratio of the area is 1.345 (Table V) .
Application of the proposed CHR-HPLC method to pharmaceutical products The CHR-HPLC method developed and validated here was used to determine the contents of the LDM enantiomers in commercial Revlimid ® capsules (Figure 2b ). No interferences of excipients were observed in the product examined; therefore, no additional extraction or separation procedures were required. The percentages of S-(−) and R-(+) LDM enantiomers, according to the label, were calculated via triplicate analysis and were found to be 100.09 ± 0.80 and 99.97 ± 0.93% for the S-and R-LDM enantiomers, respectively. The high recovery values and low RSD obtained confirmed the suitability of the proposed method for routine stereoselective LDM determination in capsules.
Discussion
Method development
Polysaccharide chiral stationary phases (CSPs) are derived from cellulose or amylase polymers. The most successful CSPs are based on benzoates or phenylcarbamate derivatives. The chiral recognition and resolving ability of the derivatives depend on their polysaccharide linkages and, therefore, on their three-dimensional structures as well as the substituents on their phenyl moieties. These substituents can interact with racemates through hydrogen bonding, dipolar interactions, π-π interactions and steric interactions to achieve chiral discrimination (23) . The CSP that gave the best separation was the LUX 5U cellulose-2-chiral column, which is a tris(3-chloro-4-methyl phenyl carbamate) derivative immobilized on silica gel (24) . Andersson et al. (23) described the separation of enantiomers on a LUX 5U cellulose-2-chiral column. The carbamate group on the CSP interacts with the solute via hydrogen bonding with the C=O and NH groups present in both the CSP and separated molecules. In addition, dipole-dipole interactions occur between the C=O group on CSP and the C=O group on the sample (24).
Method validation
The method was validated according to ICH guidelines (19) . The following validation characteristics were addressed: linearity, detection limit, quantitation limit, precision, accuracy and specificity.
Specificity
The specificity of the proposed method was evaluated to ensure that no interference products resulted from the forced degradation or excipients. LDM enantiomers were well separated under the chromatographic conditions employed here.
Linearity, LOD and LOQ
The linearity of the detector response for both LDM enantiomers was determined by plotting the ratio response (ratio peak area of the drug to that of the internal standard) versus LDM concentration. The analyte concentrations showing signal-to-noise ratios of 3 : 1 and 10 : 1 were considered to be the LOD and LOQ, respectively.
Accuracy and precision
The accuracy of the proposed method was evaluated based on the percentage relative error between the found and added concentrations of LDM enantiomers. The results obtained are shown in Table IV .
System repeatability was determined via three replicate applications and measurements of peak areas for each enantiomer. Method repeatability was determined by the %RSD values obtained by repeating the assay three times on the same day (intraday precision). LOQ (ng/mL) 2.0 2.0 LOD (ng/mL) 1.0 1.0 S a = standard deviation of the intercept; S b = standard deviation of the slope; S y/x = standard deviation of the residual. The interday precision was determined from three different runs over three successive days. Abbreviation. Er%: percentage relative error.
Intermediate precision was assessed by assays of sample sets on three different days (interday precision). The intra-and interday precision studies for the determination of both LDM enantiomers were performed at three different concentration levels, namely 25, 100 and 500 ng/mL (n = 3). The calculated RSD% values for both R-and S-LDM enantiomers determined using the proposed CHR-HPLC method is mentioned in Table IV .
Forced degradation studies
In the present study, forced degradation studies were performed to demonstrate the validity of the proposed method and to provide information regarding the specificity of the proposed method according to ICH guidelines (19) . The designed degradation experiments employed hydrolysis (acid and base), oxidation, direct daylight and dry heat were applied and the percentage recovery of the intact drug was calculated.
Conclusion
A stability-indicating stereoselective HPLC method has been developed and validated for the determination of LDM in bulk and capsule forms. The results of the stress tests, which were conducted following ICH guidelines, revealed the selectivity and stability of the proposed method as well as its applicability to quality control of LDM. LDM was found to be more stable under thermolytic and photolytic stress conditions in its solid form than in acidic or basic stress conditions in solution.
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